Haelixa Raises $5.5M Seed Round Led by Verve Ventures
Haelixa, the Swiss pioneer in DNA-based molecular tagging technology, has closed a $5.5 million seed round led by Verve Ventures, with participation from additional strategic investors. The capital will fuel commercialization of the company's platform across luxury goods, textiles, pharmaceuticals, and industrial supply chains worldwide.
A New Chapter for Molecular Traceability
In an era defined by mounting consumer demand for product authenticity and increasingly stringent regulatory requirements around supply chain transparency, Haelixa's close of this seed financing marks a pivotal milestone. Founded at ETH Zurich and spun out as an independent company, Haelixa has spent years refining a proprietary platform that encodes unique, unforgeable DNA sequences into virtually any material — from high-end leather goods to pharmaceutical excipients and raw cotton fibers.
The $5.5M seed round represents one of the most significant early-stage investments in molecular authentication to date. Led by Verve Ventures, a prominent Swiss venture capital firm with a strong track record in deep tech and life sciences, the round also includes strategic corporate backers whose involvement signals growing industry appetite for credible anti-counterfeiting and provenance solutions.
Why Investors Chose Haelixa
The investment rationale centers on the convergence of three powerful macro trends: the explosion of global counterfeiting (estimated at over $500 billion annually across all categories), tightening regulatory frameworks in Europe and North America mandating supply chain disclosure, and the maturation of synthetic DNA synthesis technologies that have dramatically reduced the cost of encoding and reading molecular markers.
Verve Ventures was drawn to Haelixa's unique technical position. Unlike serialization systems that rely on printed labels, holograms, or RFID chips — all of which can be separated from the product or replicated — Haelixa's DNA markers are physically integrated into the material itself. The marker becomes part of the product, travelling with it through every stage of manufacturing, distribution, and end use.
The investment committee was further convinced by Haelixa's growing roster of enterprise pilot customers across the luxury, textile, and life sciences verticals, as well as the team's demonstrated ability to translate fundamental molecular biology research into scalable industrial processes. The company's markers have been validated to survive extreme conditions including dyeing at 130°C, industrial washing cycles, UV exposure, and contact with industrial solvents.
CEO Patrick Strumpf on the Road Ahead
"This funding is a vote of confidence not just in our technology, but in the fundamental thesis that the world needs a better way to verify what things are made of and where they come from," said Patrick Strumpf, CEO and co-founder of Haelixa. "We have built a platform that is both scientifically rigorous and practically deployable at industrial scale. With this capital, we will accelerate our commercial rollout, deepen integration with the leading enterprise resource planning and supply chain management platforms our customers already use, and expand our laboratory infrastructure to meet growing demand for custom tagging formulations."
Strumpf emphasized that Haelixa's approach is not about replacing existing supply chain systems, but augmenting them with a layer of molecular certainty. "Brands and manufacturers already invest heavily in ERP systems, digital twins, and blockchain ledgers. But all of those digital records are only as trustworthy as the physical anchor that ties the digital to the real. Our DNA markers are that anchor — physically inseparable from the material they authenticate."
Verve Ventures' Perspective
"Haelixa represents exactly the kind of deep-tech company we look for: a genuinely differentiated technology with clear commercial pathways and a team that has the scientific credibility to execute," said a managing partner at Verve Ventures. "Molecular authentication is not a niche curiosity — it is rapidly becoming a compliance requirement across multiple sectors. We believe Haelixa is positioned to become the global standard in this space, and we are proud to support them in this next phase of growth."
Verve Ventures has a long history of backing Swiss and European deep-tech companies from seed through growth stages, with particular emphasis on technology with defensible intellectual property and strong unit economics at scale. The firm's decision to lead this round reflects its conviction that molecular traceability is transitioning from experimental to essential.
Haelixa's Technology Platform: A Primer
At the heart of Haelixa's platform is a library of synthetic DNA sequences designed specifically for industrial use. These sequences are chemically distinct from any biological DNA — they carry no genetic information and pose no ecological risk — and can be synthesized with virtually unlimited specificity. Each client or product line receives a unique molecular code, analogous to a fingerprint, that can be incorporated into liquid coatings, adhesives, dye baths, spinning finishes, or direct material treatments.
The markers are detectable at concentrations as low as parts per billion using Haelixa's proprietary field-ready reader systems, which can return a verified result in under five minutes without the need for laboratory infrastructure. For deeper forensic verification, the sequences can also be read via standard PCR and next-generation sequencing workflows available in any certified molecular biology laboratory worldwide, providing a fully independent secondary verification chain.
Key properties of Haelixa's DNA markers include:
- Material compatibility: Formulations available for aqueous, solvent-based, and polymer matrix carriers, enabling integration with leather tanning, textile finishing, metal coating, and pharmaceutical manufacturing processes.
- Thermal and chemical stability: Validated markers remain detectable after industrial dyeing at up to 130°C, repeated washing cycles, steam sterilization, and exposure to bleaching agents.
- Cryptographic uniqueness: Each DNA sequence is selected from a combinatorial space of trillions of possible codes, making duplication statistically and practically impossible without access to Haelixa's proprietary sequence library.
- Regulatory compliance: Formulations have been assessed for skin contact safety under EU REACH regulations and are compatible with food-contact material standards where required.
- Auditability: Every batch of DNA marker is logged in Haelixa's secure chain-of-custody database, enabling end-to-end audit trails from synthesis to product delivery.
Market Opportunity and Competitive Landscape
The global market for product authentication and anti-counterfeiting technologies exceeded $3.5 billion in 2024 and is projected to surpass $6 billion by 2030, driven by regulatory requirements, brand risk management, and consumer expectations. Within this market, molecular authentication — particularly DNA-based approaches — represents the highest-security tier, offering a level of verifiability that no optical or digital technology can match.
While a handful of companies globally are exploring molecular markers, Haelixa has established competitive advantages through the breadth of its validated formulations, the sensitivity and speed of its detection platform, and its experience navigating the regulatory and quality assurance requirements of regulated industries such as pharmaceuticals. The company holds a portfolio of patents covering both marker compositions and detection methodologies.
The emerging EU Digital Product Passport (DPP) regulation, which will require manufacturers to attach verified supply chain data to products across multiple categories starting in 2026, creates a further structural tailwind. Haelixa's markers are uniquely positioned as the physical authentication layer that gives DPP data legal and commercial weight.
Use of Funds
Haelixa has outlined four primary areas of investment for the seed capital:
- Commercial scale-up: Expanding the sales and business development team to accelerate customer acquisition across Europe, North America, and Asia-Pacific, with a particular focus on luxury goods manufacturers, pharmaceutical CMOs, and textile mills.
- Laboratory infrastructure: Upgrading synthesis and quality control capacity at Haelixa's Swiss facility to support increased order volumes and faster turnaround times for custom formulation development.
- Product development: Advancing next-generation reader hardware and software for field deployment, including development of a smartphone-compatible detection module targeting brand protection officers, customs authorities, and retail staff.
- Regulatory and standards engagement: Deepening engagement with ISO, GS1, and regulatory bodies in the EU and US to establish molecular DNA tagging as a recognized authentication standard in key industries.
About Haelixa
Haelixa was founded at ETH Zurich by researchers with deep expertise in synthetic biology, polymer chemistry, and industrial process engineering. The company's mission is to make the origin and authenticity of every material in global trade provable, not just claimable. Headquartered in Zurich, Switzerland, Haelixa serves enterprise customers across luxury goods, textiles, pharmaceuticals, chemicals, and specialty materials. The company's DNA-based molecular tagging platform has been deployed in production environments on three continents and authenticated materials with a combined value exceeding several hundred million euros.
For partnership inquiries, enterprise pilot programs, or investor relations, please visit haelisa.com/contact.
Published by the Haelixa Editorial Team ·